# A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6

> **NCT03255096** · PHASE1 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 39 (actual)

## Conditions studied

- Diffuse Large B-cell Lymphoma
- High-Grade B-cell Lymphoma

## Interventions

- **DRUG:** RO6870810
- **DRUG:** Venetoclax
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT03255096
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-28
- **Primary completion:** 2019-07-03
- **Final completion:** 2019-07-03
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2022-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03255096

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03255096, "A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03255096. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*